ARTICLE
27 December 2019

Staff Releases Guidance On Confidential Treatment Applications

MB
Mayer Brown

Contributor

Mayer Brown is a distinctively global law firm, uniquely positioned to advise the world’s leading companies and financial institutions on their most complex deals and disputes. We have deep experience in high-stakes litigation and complex transactions across industry sectors, including our signature strength, the global financial services industry.
On December 19, 2019, the Staff of the Division of Corporation Finance (the "Staff") released guidance detailing the process to be followed by companies that choose to submit confidential
United States Corporate/Commercial Law
To print this article, all you need is to be registered or login on Mondaq.com.

On December 19, 2019, the Staff of the Division of Corporation Finance (the "Staff") released guidance detailing the process to be followed by companies that choose to submit confidential treatment applications. In March 2019, the Securities and Exchange Commission adopted amendments that allow companies to omit confidential information that is commercially sensitive and the disclosure of which would result in competitive harm (determined on the basis of the same standard always used in connection with confidential treatment requests) from most exhibits without filing confidential treatment applications. As a result, most companies have since chosen to rely on the amended provisions and have not submitted a confidential treatment application. However, for those companies that either choose to use the traditional application method or are unable to rely on the amended provision, the Staff's guidance details the application submission process that should be followed as an alternative method. The application must include an unredacted copy of the agreement containing the confidential information, justify the time period for which confidential treatment is sought and explain why disclosure of the confidential information is unnecessary for the protection of investors. Companies that previously have obtained a confidential treatment order which is about to expire must file a short-form application to continue to protect the confidential information from public release.

A link to the Staff guidance can be found here.

Visit us at mayerbrown.com

Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe – Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

© Copyright 2019. The Mayer Brown Practices. All rights reserved.

This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More